Original article

http://dx.doi.org/10.3345/kjp.2011.54.8.329 Korean J Pediatr 2011;54(8):329-334



Clinical characteristics and outcomes among pediatric patients hospitalized with pandemic influenza A/ H1N1 2009 infection

Eun Lee, MD¹, Ju-Hee Seo, MD^{1,2}, Hyung-Young Kim, MD^{1,2}, Shin Na, MD³, Sung-Han Kim, MD³, Ji-Won Kwon, MD⁴, Byoung-Ju Kim, MD⁵, Soo-Jong Hong, MD^{1,2}

¹Department of Pediatrics, ²Childhood Asthma Atopy Center, Asan Medical Center Children's Hospital, Seoul, ³Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, ⁴Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, ⁵Department of Pediatrics, Inje University Haeundae Paik Hospital, Busan, Korea

Received: 5 April 2011, Revised: 26 May, 2011 Accepted: 13 June 2011 Corresponding author: Soo-Jong Hong, MD Department of Pediatrics, Childhood Asthma Atopy Center, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, 388-1 Pungnap-dong, Songpa-gu, Seoul 138-736, Korea Tel: +82-2-3010-3379, Fax: +82-2-473-3725 E-mail: sjhong@amc.seoul.kr **Purpose:** The purpose of this article is to describe the clinical and epidemiologic features and outcomes among children hospitalized with pandemic influenza A/H1N1 2009 infection.

Methods: We retrospectively reviewed the charts of hospitalized pediatric patients (<18 years) diagnosed with pandemic influenza A/H1N1 2009 infection by reverse-transcriptase polymerase chain reaction at a tertiary hospital in Seoul, Korea, between September 2009 and February 2010.

Results: A total of 72 children were hospitalized with pandemic influenza A/H1N1 2009 infection (median age, 6.0 years; range, 2 months to 18 years). A total of 40% had at least 1 underlying medical condition, including asthma (17%), malignancies (19%), and heart diseases (17%). Of the 72 patients, 54 (76%) children admitted with H1N1 infection showed radiographic alterations compatible with pneumonia. There was no significant difference in pre-existing conditions between pandemic influenza A/H1N1 infected patients with or without pneumonia. Children with pandemic influenza A/H1N1 pneumonia were more likely to have a lower lymphocyte ratio (P=0.02), higher platelet count (P=0.02), and higher level of serum glucose (P=0.003), and more commonly presented with dyspnea than did those without pneumonia (P=0.04).

Conclusions: No significant differences in age, sex, or presence of preexisting conditions were found between children hospitalized with pandemic influenza A/H1N1 H1N1 influenza infection with pneumonia and those without pneumonia. Higher leukocyte count, higher glucose level, and a lower lymphocyte ratio were associated with the development of pandemic A/H1N1 2009 influenza pneumonia.

Copyright © 2011 by The Korean Pediatric Society

Key words: H1N1, Pneumonia, Children, Hospitalization

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/bync/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

The pandemic influenza A/H1N1 viral infection was first identified in March 2009¹⁾; this virus was antigenically and genetically unrelated to human seasonal influenza viruses, but genetically related to viruses known to circulate in swine²⁾. The world experienced its first wave of pandemic influenza A/H1N1 activity in the spring of 2009, followed by a second wave in the fall, peaking at the end of October. An early report on 18 hospitalized patients who were victims of the initial outbreak in Mexico showed that the pandemic H1N1 2009 virus caused severe illness and death in previously healthy young to middle-aged individuals; it has since been noted that the majority of patients continue to experience mild illness¹⁾.

There have been a few reports of H1N1 characteristics and outcomes among children hospitalized with pandemic influenza A/H1N1 2009 viral infection^{3,4)}. Although children are considered to be more vulnerable to pandemic influenza pneumonia, few reports describe the characteristics of this pneumonia in pediatric patients^{5,6)}. This study describes the clinical and epidemiologic features of the viral infection among pediatric patients hospitalized with pandemic influenza A/H1N1 pneumonia from September 2009 to February 2010 at a tertiary medical center in Korea.

Materials and methods

We reviewed the medical charts and radiologic and laboratory findings of all children admitted to Asan Children's Hospital in Korea between September 2009 and February 2010; the hospital is a tertiary, academic medical center.

We included children with pandemic influenza H1N1 confirmed by reverse-transcription polymerase chain reaction (RT-PCR). The clinical criteria for a diagnosis of H1N1 pneumonia in the hospitalized pediatric patients was based on abnormal breath sound such as crackle, rale, or rhonchi and opacities found on the chest radiography at admission. The chest radiographs were reviewed by two radiologists, and final decisions on the findings were reached by consensus.

Clinical characteristics were compared between patients with pandemic A/H1N1 pneumonia and those with pandemic A/H1N1 infection and between children less than 5 years and those older than 5 years. Patients who were admitted because of pandemic influenza A/H1N1 infection were also subcategorized by clinical outcome as those requiring respiratory support by nasal cannula, those requiring mechanical ventilation, and those requiring admission to the intensive care urnit (ICU).

1. Microbiological studies

Nasopharyngeal swab specimens (Flexible Minitip 503CS01 Flock Swabs, Diagnostic Hybrids, Athens, OH, USA) were collected at admission. Specimens were placed in 3 Ml Universal Transport Medium (Diagnostic Hybrids) and kept at 2 to 4°C. RT-PCR testing was done in accordance with published guidelines from the U.S. Centers for Disease Control and Prevention.

2. Statistical analysis

We compared data between patients with pandemic H1N1 pneumonia and those with pandemic H1N1 infection without pneumonia. Logistic regression was used to identify the characteristics of the children in each group. The Fisher's exact test was used to compare categorical variables. Statistical analysis was performed with the SPSS ver. 16.0 (SPSS Inc., Chicago, IL, USA). A *P* value of less than 0.05 indicated a significant difference.

Results

1. Patient characteristics

In our institution, 11,662 pediatric patients (all under 18 years of age) were tested for pandemic influenza A/H1N1 2009 from September 2009 to February 2010 (Table 1). Among them, 5,367 patients (46%) tested positive; 72 of the 5,367 patients were admitted to the hospital, and 54 of these 72 patients had pandemic influenza A/H1N1 pneumonia confirmed by means of RT-PCR (Table 2). The epidemic curve of pediatric patients hospitalized with pandemic influenza A/H1N1 with or without pneumonia in Korea is shown in Fig. 1. Of these 72 patients, 54 (75%) were male. The median age was 6.0 years. Fig. 2 shows the age distribution of children hospitalized with pandemic H1N1 pneumonia or pandemic H1N1 infection alone. Of the 18 children without pneumonia, 17 were diagnosed with upper respiratory infection and the remaining 1 patient was diagnosed with Kawasaki disease.

Table 1. Analyses	of	Patient	Variables	from	September	2009	to
February 2010							

Variables	Value
Total number of patients hospitalized with any disease during the study period	5,829
Number of patients hospitalized with pneumonia during the study period	112
Number of patients who underwent RT-PCR for detection of pandemic influenza A/H1N1 2009	11,662
Positive results	5,367 (46%)
Negative results	6,295 (54%)

Values are presented as no. of patients or no. of patients (%). RT-PCR, reverse-transcriptase polymerase-chain-reaction.

Variable	H1N1 pneumonia (n=54)	Non- pneumonia (n=18)	All patients (n=72)	P value*	
Age (yr)				0.924	
Median	6.0	6.5	6.0		
Range	2 mo-18 yr	1 yr-18 yr	7.8 yr		
All patients, n/total n (%)					
<5 yr	9/54 (17)	5/18 (28)	14/72 (19)		
≥5 to <10 yr	34/54 (63)	6/18 (33)	40/72 (56)		
≥10 to <15 yr	2/54 (4)	3/18 (17)	5/72 (7)		
≥15 to ≤18 yr	9/54 (17)	4/18 (22)	13/72 (18)		
Sex, n (%)				0.349	
Male	42 (78)	12 (67)	54 (75)		
Female	12 (22)	6 (33)	18 (25)		
Preexisting condition,					
n/total n (%)	16/54 (30)	13/18 (72)	29/72 (40)	0.242	
Asthma exacerbation	3/16 (19)	1/13 (8)	4/29 (14)	0.343	
Asthma 1st attack	1/16 (6)	-	1/29 (3)	>0.999	
Cancer	3/16 (19)	2/13 (15)	5/29 (19)	>0.999	
Heart disease	3/16 (19)	2/13 (15)	4/29 (17)	>0.999	
Neurologic disease	1/16 (6)	2/13 (15)	3/29 (10)	0.573	
Immunosuppression	-	2/13 (15)	2/29 (7)	0.192	
Other diseases (atopic dermatitis, anemia, headache)	3/16 (20)	4/13 (31)	7/29 (24)	0.667	
Endocrine disease	1/16 (6)	-	1/29 (3)	>0.999	
Renal disease	1/16 (6)	-	1/29 (3)	>0.999	

Table 2. Epidemiologic Features, Preexisting Conditions, Clinical Symptoms in Children Hospitalized with 2009 H1N1 Influenza

*Fisher's exact test was used when cell sizes were small.




Fig. 1. Seasonal pattern of hospitalization of children for pandemic H1N1 influenza with or without pneumonia.

2. Preexisting medical conditions

A total of 40% of patients had at least 1 preexisting medical condition: 30% and 72% in the H1N1 pneumonia group and the group without pneumonia (P=0.24), respectively. In the H1N1 pneumonia group, asthma was the most common medical condition (25%), and the children presented with exacerbation of asthma or a first attack.




Fig. 2. Age distribution of children hospitalized for pandemic H1N1 influenza with or without pneumonia.

 Table 3. Clinical Symptoms in Children Hospitalized with 2009 H1N1

 Pneumonia or without Pneumonia

Symptoms	H1N1 pneumonia (n=54)	Non- pneumonia (n=18)	All patients (n=72)	P value
Fever (≥ 37.8°C)	53 (98)	17 (94)	70 (97)	0.999
Fatigue	1 (2)	-	1 (1)	1.000
Nasal stuffness	2 (4)	2 (11)	4 (6)	0.999
Sore throat	11 (20)	2 (11)	13 (18)	0.763
Rhinorrhea	11 (20)	7 (39)	18 (25)	0.054
Cough	53 (98)	14 (78)	67 (93)	0.998
Sputum	24 (44)	5 (28)	29 (40)	0.390
Wheezing	6 (11)	1 (6)	7 (10)	0.953
Dyspnea	35 (65%)	2 (11)	37 (51)	0.036
Chest pain	2 (4)	-	2 (3)	0.999
Diarrhea	1 (2)	1 (6)	2 (3)	0.999
Nausea	3 (6)	4 (22)	7 (10)	0.184
Vomiting	5 (9)	4 (22)	9 (13)	0.525

Values are presented as no. of patients (%).

3. Clinical features

Fever (temperature above 37.8°C) and cough were the most common presentations at admission in both groups (Table 3). The next most common symptom was dyspnea in the pandemic H1N1 pneumonia group (n=35, 65%), and rhinorrhea (n=7, 39%) in the group without pneumonia. Nausea and vomiting were more common in the group without pneumonia (22% for both symptoms) compared with the pandemic pneumonia group (6% and 9%, respectively); however, this difference was not significant. Sputum was a more common symptom in children older than 5 years than those aged less than 5 years.

4. Laboratory tests on admission

Children with pandemic H1N1 pneumonia were more likely to have a lower lymphocyte ratio (P=0.02), higher platelet counts

Laboratory results	H1N1 pneumonia (n=54)	Non-pneumonia (n=18)	All patients (n=72)	P value
Leukocyte count/mm ³				
Median (IQR)	11,300 (9,050-15,250)	9,100 (6,650-11,300)	10,600 (8,100-14,600)	0.029
Lymphocyte, (%)				
Median (IQR)	7.05 (4.5-14.0)	15.6(8.9-35.8)	8.0 (5.5-17.4)	0.020
Hematocrit, (%)				
Median (IQR)	39.1 (36.6-42.0)	39.6 (34.6-42.2)	39.2 (36.5-42.0)	0.229
Platelet count/mm ³				
Median (IQR)	273.5 (208.0-316.0)	226.0 (190.5-240.5)	201-310 (75-448)	0.020
Creatinine, (mg/dL)				
Median (IQR)	0.5 (0.4-0.7)	0.4 (0.35-0.60)	0.5 (0.4-0.6)	0.407
CRP, (mg/dL)				
Median (IQR)	3.0 (1.1-5.2)	1.27 (0.4-5.12)	2.73 (0.82-5.16)	0.841
Glucose, (mg/dL)				
Median (IQR)	123.0 (106.8-142.0)	102.0 (94.0-11.20)	119.0 (101.0-137.0)	0.003

Table 4. Results of Laboratory Tests in Children Hospitalized with Pandemic Influenza A/H1N1 2009 Pneumonia or without Pneumonia

IQR, interquartile range; CRP, C-reactive protein.

Table 5. Distribution	and	Radiologic	Findings	in	the	H1N1	Pneumoni	ia
Group								

aroup	
Variables	Value
Distribution	
Unilateral	20/54 (37)
Bilateral	34/54 (63)
Fingings	
Bronchopneumonia	34/54 (63)
Consolidation	23/54 (43)
Bronchopneumonia+consolidation	3/54 (6)

Values are presented as number/total number (%).

(*P*=0.02), and a higher level of serum glucose (*P*=0.003) than those without pneumonia (Table 4).

5. Radiographic evaluation

Chest radiography was performed in all children admitted with pandemic influenza A/H1N1 infection; 54 children (75%) had findings consistent with pneumonia. On an average, the initial chest radiographs for all patients (n=72) were obtained 1.2 days (range, 0 to 7 days) after the onset of clinical symptoms. In the pandemic H1N1 pneumonia group, initial chest radiography revealed unilateral abnormalities in 37%, bronchopneumonial pattern in 57% (n=31), consolidation patterns in 43 % (n=20), and mixed patterns in 6% (n=3) (Table 5). The chest computed tomography scans obtained for 11 of these patients showed bilaterally distributed lung parenchymal lesions that had peribronchial ground-glass opacities (n=7), patchy consolidations (n=5), and interstitial thickening (n=1). The mediastinal and perihilar lymph nodes were detected in 1 patient, pleural effusion was noted in 3 patients, and pneumomediastinum was detected in 2 patients.

6. Severity of illness and outcomes

Oxygen supplementation was provided to 67% of the children hospitalized with pandemic H1N1 pneumonia, and to 6% of children without pneumonia. Three patients were admitted to the ICU. Of the 3 pediatric patients who required mechanical ventilation, 2 were male, and the sole female had a preexisting hematologic malignancy, and hers was the only death in this study. This patient had a 2-day history of fever, cough, and sputum. Her initial laboratory results were as follows: leukocyte count 3,300/mm³, platelet count 75,000/mm³, aspartate aminotransferase 400 IU/ L, alanine aminotransferase 305 IU/L, lactate dehydrogenase 977 IU/L, C-reactive protein 0.82 mg/dL, and creatine kinase 24 IU/ L. She received oseltamivir (150 mg twice a day), amatadine (100 mg twice a day), azithromycin, ceftazidime and vancomycin until her death on hospital day 17. She remained positive for influenza A RNA as assessed by RT-PCR 2 days after administration of antiviral medication; no other viral pathogens were cultured and amplified by PCR when bronchoalveolar lavage (BAL) and sputum samples were taken, and bacterial cultures from the same specimens showed no growth. Complications in this patient included hypovolemic shock and respiratory failure.

7. Treatment

All pediatric patients suspected having pandemic H1N1 infection were administered oseltamivir before the results of the H1N1 RT-PCR were known. The median time from the onset of symptoms to the initiation of antiviral therapy was 1.1 days (range, 0 to 5 days) in the pneumonia group and 1.7 days (range, 0 to 7 days) in the group without pneumonia; this difference was not significant (P=0.24). Antibiotics were administered to 94% of patients in the pandemic H1N1 pneumonia group, and to 61% of those without pneumonia. Oseltamivir resistance does not performed in all patients.

Discussion

Children admitted to a tertiary hospital in Korea with pandemic influenza A/H1N1 2009 infection during the second wave of the pandemic showed a wide spectrum of disease, ranging from upper respiratory infection alone to severe illness and death.

The chest radiography findings on admission were consistent with those for pneumonia in 54 (75%) of the pediatric patients hospitalized with pandemic influenza A/H1N1 2009 infection. However, no significant differences were observed between the pandemic influenza A/H1N1 2009 pneumonia group and the pandemic influenza A/ H1N1 2009 infection group with respect to age, sex, or the presence of preexisting conditions. In addition, no significant differences were observed between these groups with respect to the time between the onset of symptoms and the initiation of oseltamivir therapy (pneumonia group: mean period, 1.1 days; non-pneumonia group: mean period, 1.7 days). The patients from the pandemic influenza A/ H1N1 2009 pneumonia group had higher leukocyte counts, higher glucose levels and lower lymphocyte ratios than did the patients from the group without pneumonia.

Some reports have suggested that children less than 5 years old are at the highest risk of seasonal influenza-associated hospitalizations⁷⁻⁹; in our study, pediatric patients aged 5 to 18 years accounted for 83% of patients in the pandemic H1N1 pneumonia group and 72% of those in the pandemic H1N1 group without pneumonia (Table 2). In a study on patients hospitalized with 2009 H1N1 influenza in the United States, the study population included a greater proportion of children older than 5 years (29%) than of children younger than 5 years (15%)¹⁰. Children aged less than 5 years were hospitalized more frequently because of either different admission criteria or diagnostic method for pneumonia in each hospital. Therefore, we cannot definitely conclude that children aged less than 5 years are at the highest risk for influenza-associated hospitalization. The median duration of viral shedding, as determined by positive RT-PCR results, was 2.0 days for children younger than 5 years and 3.81 days for children older than 5 years (P=0.59). The reason for this age distribution and for the difference in the duration of viral shedding for each age group is uncertain; however, these findings may be related to the higher possibilities of contact with and of repeated or prolonged exposure to this virus in the case of children older than 5

years at schools.

Approximately one-quarter to one-half of patients with pandemic influenza A/H1N1 2009 viral infection who were hospitalized or who died had no reported coexisting medical conditions¹⁰⁻¹³⁾. In our study, 40% of pediatric patients with pandemic H1N1 infection had preexisting conditions. However, there was no significant difference between patients in the pandemic H1N1 pneumonia group and those in the group without pneumonia. The pandemic influenza A/H1N1 2009 virus causes pneumonia regardless of preexisting medical conditions; this may be because the virus has a strong affinity for the lower respiratory tract and the affected population did not have antibodies specific to this virus^{1,2,14)}.

In our study, dyspnea was the only clinical feature at presentation that differed significantly between patients in the pandemic H1N1 pneumonia group and those in the group without pneumonia. Because we considered shortness of breath or breathing discomfort to be indicative of dyspnea, there was no significant difference in respiratory rates between the groups.

The risk factors for pandemic influenza A/H1N1 pneumonia are still unclear; however, a significantly greater number of the patients with pneumonia presented with higher leukocyte counts, higher glucose levels and lower lymphocyte ratios than did the patients without pneumonia. In a few studies, patients admitted with pandemic influenza A/H1N1 infection showed increased serum concentrations of lactate dehydrogenase and creatinine kinase^{1,15)}. In our study, the presence of pandemic H1N1 pneumonia did not affect these levels, but the level of glucose was elevated in the pandemic H1N1 pneumonia group, compared with the group without pneumonia. The most likely explanation for this may be the stress effect of H1N1 infection complicated by pneumonia.

The radiographs for patients with pandemic influenza A/ H1N1 pneumonia showed prominent peribronchial marking with hyperinflation, similar to that observed in other common viral respiratory infections¹⁶. In contrast, the radiographs for children with a more severe clinical course of pandemic influenza A/H1N1 infection typically show a bilateral symmetrical distribution pattern of areas of consolidation that are often associated with ground-glass opacification. In this study, the patients (n=6) who were admitted to the ICU or required mechanical ventilation had bilateral symmetric distribution of consolidation or ground-glass opacities.

The rate of bacterial or other viral co-infection was 4.2%; 1 patient was co-infected with respiratory syncytial virus and mycoplasma in the pandemic influenza A/H1N1 pneumonia group, and 2 patients with adenovirus and streptococcal pneumonia, in the pandemic influenza A/H1N1 group without pneumonia. We could not find any relationship between co-infections and the severity of disease;

these 3 patients did not need any oxygen supplementation and were not admitted to the ICU.

A study performed between May and July 2009 showed that the hospitalization rate for pandemic influenza A/H1N1 among children was twice that for 2008 seasonal influenza in the same population. Moreover, the death rate was 10 times the rate associated with seasonal influenza for the same population in $2007^{4,17}$. In contrast to the findings of these studies, the results of another study reported that the overall hospital mortality rates for all age groups was 1.1 % and that for children was 0.24% in Japan¹⁸⁾. In our study, the death rate due to pandemic influenza A/H1N1 2009 was low (1.4%), although there is some limitation due to small sample size. These differences may be partially due to the recommendation, which was put forth in September 2009 in Korea, that empirical therapy with oseltamivir be administered to patients with influenza-like symptoms-especially to children at high-risk and children who were hospitalized; the differences may also exist because the other studies included both pediatric and adult patients.

Our study includes a limited number of cases and was of short duration. The need for hospitalization due to pandemic influenza A/ H1N1 2009 infection was decided by several attending physicians without any objective indications. The availability of hospital or ICU beds may have influenced assessment of the severity of disease. This study cannot represent the full spectrum of pandemic influenza A/H1N1 2009 influenza infections because it was performed at a tertiary hospital.

In conclusion, hospitalization with pandemic H1N1 influenza infection affected children without any significant differences in age, sex, or the presence of preexisting conditions between the pandemic H1N1 pneumonia group and those without pneumonia. A higher leukocyte count, higher glucose level and a lower lymphocyte ratio together with dyspnea were associated with the development of pandemic influenza A/H1N1 2009 influenza pneumonia.

Acknowledgement

The authors thank all the patients involved in this report and all the pediatricians and hospital staff involved in their care.

References

- Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, Hernandez M, Quiñones-Falconi F, Bautista E, et al. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med 2009;361:680-9.
- 2. Peiris JS, Poon LL, Guan Y. Emergence of a novel swine-origin influenza

A virus (S-OIV) H1N1 virus in humans. J Clin Virol 2009;45:169-73.

- Shin SY, Kim JH, Kim HS, Kang YA, Lee HG, Kim JS, et al. Clinical characteristics of Korean pediatric patients critically ill with influenza A (H1N1) virus. Pediatr Pulmonol 2010;45:1014-20.
- Libster R, Bugna J, Coviello S, Hijano DR, Dunaiewsky M, Reynoso N, et al. Pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1) in Argentina. N Engl J Med 2010;362:45-55.
- Lister P, Reynolds F, Parslow R, Chan A, Cooper M, Plunkett A, et al. Swine-origin influenza virus H1N1, seasonal influenza virus, and critical illness in children. Lancet 2009;374:605-7.
- Centers for Disease Control and Prevention (CDC). Surveillance for pediatric deaths associated with 2009 pandemic influenza A (H1N1) virus infection - United States, April-August 2009. MMWR Morb Mortal Wkly Rep 2009;58:941-7.
- Sachedina N, Donaldson LJ. Paediatric mortality related to pandemic influenza A H1N1 infection in England: an observational populationbased study. Lancet 2010;376:1846-52.
- World Health Organization. Global alert and response: current WHO phase of pandemic alert? [Internet]. Geneva: World Health Organization; c2011. [cited 2009 Nov 12]. Available from: www.who.int/csr/disease/ avian_influenza/phase/en/index.html.
- 9. Coffin SE, Zaoutis TE, Rosenquist AB, Heydon K, Herrera G, Bridges CB, et al. Incidence, complications, and risk factors for prolonged stay in children hospitalized with community-acquired influenza. Pediatrics 2007;119:740-8.
- Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, Louie J, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009;361:1935-44.
- Ampofo K, Gesteland PH, Bender J, Mills M, Daly J, Samore M, et al. Epidemiology, complications, and cost of hospitalization in children with laboratory-confirmed influenza infection. Pediatrics 2006;118:2409-17.
- Izurieta HS, Thompson WW, Kramarz P, Shay DK, Davis RL, DeStefano F, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 2000;342:232-9.
- Centers for Disease Control and Prevention (CDC). 2009 pandemic influenza A (H1N1) virus infections - Chicago, Illinois, April-July 2009. MMWR Morb Mortal Wkly Rep 2009;58:913-8.
- Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, Hatta M, et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009;460:1021-5.
- Kumar A, Zarychanski R, Pinto R, Cook DJ, Marshall J, Lacroix J, et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 2009;302:1872-9.
- Lee EY, McAdam AJ, Chaudry G, Fishman MP, Zurakowski D, Boiselle PM. Swine-origin influenza a (H1N1) viral infection in children: initial chest radiographic findings. Radiology 2010;254:934-41.
- Nguyen-Van-Tam JS, Openshaw PJ, Hashim A, Gadd EM, Lim WS, Semple MG, et al. Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May-September 2009). Thorax 2010;65:645-51.
- Nishiyama M, Yoshida Y, Sato M, Nishioka M, Kato T, Kanai T, et al. Characteristics of paediatric patients with 2009 pandemic influenza A(H1N1) and severe, oxygen-requiring pneumonia in the Tokyo region, 1 September-31 October 2009. Euro Surveill 2010;15. pii:19659.